Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Bowlus

Showing results (151-160 of 189) with videos related to

Pageof 19
Sort By:
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2017
Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health SystemsMei Lu, Jia Li, Irina V Haller, et al.
Hepatology (Baltimore, Md.)|May 5, 2017
Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobioticsToshihiro Tanaka, Weici Zhang, Ying Sun, et al.
Hepatology (Baltimore, Md.)|July 8, 2011
Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosisMasanobu Tsuda, Yoko M Ambrosini, Weici Zhang, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosisGuanghua Rong, Renqian Zhong, Ana Lleo, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2021
Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycansEmanual Maverakis, Alexander A Merleev, Dayoung Park, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 4, 2024
Anti-integrin αvβ6 Autoantibodies are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease SeverityHannah Bloemen, Alexandra E Livanos, Adrielly Martins, et al.
Clinical Epidemiology|November 18, 2020
Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary CholangitisMei Lu, Christopher L Bowlus, Keith Lindor, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Hepatology (Baltimore, Md.)|June 10, 2022
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASHJun Xu, Ya Wang, Mina Khoshdeli, et al.
Pageof 19

Showing results (151-160 of 189) with videos related to

Sort By:
Pageof 19
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2017
Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health SystemsMei Lu, Jia Li, Irina V Haller, et al.
Hepatology (Baltimore, Md.)|May 5, 2017
Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobioticsToshihiro Tanaka, Weici Zhang, Ying Sun, et al.
Hepatology (Baltimore, Md.)|July 8, 2011
Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosisMasanobu Tsuda, Yoko M Ambrosini, Weici Zhang, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosisGuanghua Rong, Renqian Zhong, Ana Lleo, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2021
Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycansEmanual Maverakis, Alexander A Merleev, Dayoung Park, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 4, 2024
Anti-integrin αvβ6 Autoantibodies are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease SeverityHannah Bloemen, Alexandra E Livanos, Adrielly Martins, et al.
Clinical Epidemiology|November 18, 2020
Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary CholangitisMei Lu, Christopher L Bowlus, Keith Lindor, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Hepatology (Baltimore, Md.)|June 10, 2022
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASHJun Xu, Ya Wang, Mina Khoshdeli, et al.
Pageof 19